Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 6Unknown 4Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Pain 1Ovarian Neoplasms 1Neoplasms 1Multi-organ Metastatic Colorectal Cancer 1Lymphatic Metastasis 1Cholangiocarcinoma 1Carcinoma, Medullary 1Breast Neoplasms 1Agnosia 1

Interventions

Magnetic Resonance Spectroscopy 9pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × Radiofrequency Ablation × Clear all
NCT02482454 2017-08-01

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

The First People's Hospital of Changzhou

Phase 2/3 Active not recruiting
50 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡